HONG KONG, SHANGHAI and FLORHAM PARK, N.J. — September 28, 2026
HUTCHMED (China) Limited announced the initiation of the Phase Ia portion of a global Phase I clinical trial of HMPL-A830, an investigational KRAS-payload antibody-targeted therapy conjugate (ATTC) for patients with unresectable, advanced or metastatic solid tumors. The first patient received the first dose in China on September 24, 2026. HMPL-A830 combines a selective KRAS small-molecule inhibitor payload with an anti-EGFR antibody and is designed to deliver the KRAS-targeting payload to EGFR-expressing tumor cells while simultaneously inhibiting EGFR and KRAS signaling.
HMPL-A830 Combines EGFR Targeting With KRAS Inhibition
HMPL-A830 is designed as a first-in-class KRAS-payload ATTC that combines antibody-guided delivery with dual pathway inhibition. The candidate uses an anti-EGFR antibody to target tumor cells expressing EGFR and carries a potent KRAS inhibitor as its payload. HUTCHMED said the approach is intended to address limitations associated with systemic administration of KRAS inhibitors, including pathway-related toxicities in normal tissues, while simultaneously blocking EGFR signaling that can contribute to resistance to KRAS-targeted therapies. Colorectal, pancreatic and lung cancers contain substantial populations of KRAS-altered tumors, creating potential applications for a targeted approach to KRAS biology. However, HMPL-A830 remains investigational, and its clinical safety and efficacy are not yet established.
Phase I Study Evaluates Safety and Preliminary Activity
The first-in-human Phase I study is evaluating HMPL-A830 in patients with advanced or metastatic solid tumors, with the initial Phase Ia dose-escalation portion designed to characterize safety and tolerability and determine the maximum tolerated dose and recommended dose for expansion. Additional assessments include pharmacokinetics, immunogenicity and preliminary antitumor activity. A subsequent dose-expansion and optimization portion is planned to further evaluate safety, tolerability and preliminary activity in selected solid-tumor indications. The study is multicenter and open-label and is registered as NCT07718581. Because the program has only recently entered clinical testing, future clinical data will be needed to determine whether the preclinical rationale translates into meaningful patient benefit.
Advertisement
HUTCHMED and GSK Advance Global Development Strategy
HUTCHMED is responsible for the global Phase I development program for HMPL-A830 under an exclusive development and license agreement with a GSK subsidiary. Under the agreement announced September 3, 2026, GSK receives worldwide development and commercialization rights outside Mainland China, Hong Kong, Macau and Taiwan, subject to customary closing conditions, including completion of applicable antitrust reviews. HUTCHMED’s ATTC platform combines monoclonal antibodies with proprietary small-molecule inhibitor payloads and is intended to develop targeted therapies with complementary mechanisms of action. The start of clinical development marks the first human evaluation of HMPL-A830 and advances HUTCHMED’s strategy of using antibody-guided delivery to address challenging targets in precision oncology.
Source :HUTCHMED press release
